Rebecca Fitzgerald

Fitzgerald’s postdoctoral work took place at the Department of Adult and Paediatric Gastroenterology at St Bartholomew’s Hospital and at The Royal London School of Medicine and Dentistry, where she was supervised by Michael Farthing and funded by an MRC Clinical Scientist award.

In recognition of her work on Cytosponge and the early treatment of Barrett’s oesophagus, Fitzgerald was awarded the Westminster Medal in 2004. In 2008, she was the recipient of a Lister Prize Fellowship, and in 2008 she received an NHS Innovation Prize. In 2013, Fitzgerald won an NIHR Research Professorship for her work.

The Royal College of Physicians appointed Fitzgerald as its Goulstonian Lecturer. She was also awarded the British Society of Gastroenterology’s Sir Francis Avery Jones Award. In 2013, Fitzgerald was elected as a Fellow of the Academy of Medical Sciences. Fitzgerald has also won a grant from the Evelyn Trust “as she works to develop effective screening that will benefit patients worldwide.”. In 2018, Fitzgerald was awarded the Jane Wardle Prevention and Early Diagnosis prize, which recognises individuals who have produced world-leading research in the field of prevention and early detection of cancer.

After her postdoctoral positions, Fitzgerald began her own research group at the MRC Cancer Unit in Cambridge. In 2004, Fitzgerald and her group developed Cytosponge, a novel screening test for Barrett’s oesophagus, a common precursor to the often deadly cancer oesophageal adenocarcinoma. Cytosponge consists of a pill-sized capsule that contains a sponge, and is attached to a string. The capsule is swallowed, which expands into a sponge in the stomach. The sponge is then pulled out by the string, collecting cells from the oesophageal wall along the way. Subsequent biological analysis of the collected cells determines whether a patient has Barrett’s. Cytosponge has been praised for its minimally invasive, economical design compared to the current standard for identifying Barrett’s oesophagus, the endoscopy. The procedure is now in its third clinical trial, which will see it tested on 9,000 patients in the UK.

Fitzgerald received a MA Cantab and a MB BChir in Medicine from Girton College, Cambridge in 1992. In 1997, she completed an MD at Stanford University under the guidance of George Triadafilopoulos.

Rebecca Fitzgerald FMedSci is a British medical researcher (born September 1968) whose work focuses on the early detection and treatment of oesophageal cancers. She is a tenured Professor of Cancer Prevention and Program Leader at the Medical Research Council Cancer Unit of the University of Cambridge. In addition to her professorship, Fitzgerald is currently the Director of Medical Studies for Trinity College, Cambridge, where she is also a Fellow. She is also an Honorary Consultant in Gastroenterology and General Medicine at Cambridge’s Addenbrooke's Hospital. She is also the co-leader of the CRUK Cambridge Institute Early Detection Programme.